Cabaletta Bio, Inc.
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its CABA® platform uses chimeric antigen receptor T cells for autoimmunity, with lead candidate resecabtagene autoleucel (rese-cel), a CD19-directed CAR T therapy designed to deplete B… From the company’s description.
In fiscal 2025, Cabaletta Bio, Inc. reported a net loss of $167.86M. Operations used $131.08M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cabaletta Bio, Inc. does
In the company’s own words
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its CABA® platform uses chimeric antigen receptor T cells for autoimmunity, with lead candidate resecabtagene autoleucel (rese-cel), a CD19-directed CAR T therapy designed to deplete B cells and potentially reset the immune system after a single infusion. Cabaletta is evaluating rese-cel in clinical trials for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, including trials assessing use without preconditioning; it initiated a registrational myositis trial in December 2025. The company’s development portfolio also includes a legacy engineered cell therapy program, while its current clinical focus is rese-cel. Cabaletta relies on external manufacturing partners, including Minaris, Lonza and Cellares, for clinical supply and is developing processes intended to support later-stage trials and potential commercial production. Founded in 2017, the company grew from research combining expertise in B cell-mediated autoimmune disease and CAR T cell design. Its website is https://cabalettabio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1759138
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cabaletta Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cabaletta Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cabaletta Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cabaletta Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cabaletta Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”